Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹943.90down ₹15.90 (1.66%)BSE ₹945.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹959.80.
28 Oct: open ₹953.30, high ₹959.80, low ₹936.40
52-week range of traded prices to 28 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,035 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.70
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 36.55
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.12
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 57,06841.5% delivered
Jubilant Pharmova board and management
55 filed, newest first. Page 2 of 2.
Nov 2010
11 Nov · Management
Mr. Arabinda Ray, an Independent Director of the Company has resigned from the Board with effect from November 11, 2010.
Jul 2010
30 Jul · Management
Mr. Rahul Yadav, Nominee Director of Citicorp International Finance Corporation and HPC (Mauritius) Limited, has resigned from the Board with effect from July 07, 2010. Consequently, Mr Vishal Marwaha has also ceased to be Alternate Director to Mr. Rahul Yadav.7 Jul · Management
Mr. Rahul Yadav, Nominee Director of Citicorp International Finance Corporation and HPC (Mauritius) Limited, has resigned from the Board with effect from July 07, 2010. Consequently, Mr Vishal Marwaha has also ceased to be Alternate Director to Mr. Rahul Yadav.
Mar 2010
15 Mar · Management
Mr. Shardul S. Shroff has been appointed as Additional Director of the Company with effect from March 15, 2010. He will be an independent director.
Oct 2008
14 Oct · Management
A) Mr. Ajay Relan has ceased to be Director of the Company. Further Mr. Vishal Marwaha has ceased to be Alternate Director to Mr. Ajay Relan. b) Mr. Rahul Yadav has been appointed as Additional Director on the Board of Directors of the Company with effect from October 14, 2008. Further Mr. Vishal Marwaha has been appointed as Alternate Director to Mr. Rahul Yadav with effect from October 14, 2008. c) The Board of Directors have decided to increase the number of Employee Stock Options from existing 7,17,500 options (giving right to acquire upto 35,87,500 equity shares of Re.1/- each) to 11,00,000 options (giving right to acquire upto 55,00,000 equity shares of Re.1/- each), subject to members approval, to be granted to eligible employees either by way of subscription to fresh shares or through trust route.